Paolo Manzoni, MD, PhD

University of Torino
Torino, Piemonte, Italy

Disclosure(s): Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD): Advisor/Consultant, SAC member for MSD

Presentation(s):

• 167 - Phase 3, Randomized, Controlled Trial Evaluating Safety, Efficacy, and Pharmacokinetics (PK) of Clesrovimab in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease

  Thursday, October 17, 2024
  2:21 PM – 2:33 PM US PT